Synergistic effect of methionine encephalin (MENK) combined with pidotimod(PTD) on the maturation of murine dendritic cells (DCs)

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 4, 2013, Pages 773-783

  Meng, Yiming ^a   Wang, Qiushi ^a   Zhang, Zhenjie ^a   Wang, Enhua ^a   Plotnikoff, Nicollas P ^b   Shan, Fengping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b TNI Biotech Company   (United States)

Author keywords

BMDCs; Maturation; MENK; PTD; Synergistic effect

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METENKEPHALIN; PIDOTIMOD; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CELL CULTURE; CELL MATURATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENDOCYTOSIS; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; PHENOTYPE; T LYMPHOCYTE; UPREGULATION;

BMDCS; MATURATION; MENK; PTD; SYNERGISTIC EFFECT;

ANIMALS; ANTIGENS, CD; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; ENDOCYTOSIS; ENKEPHALIN, METHIONINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOLOGIC FACTORS; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; MICROSCOPY; PYRROLIDONECARBOXYLIC ACID; T-LYMPHOCYTES; THIAZOLIDINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877134147     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23137     Document Type: Article

References (69)

1. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975; 258:577-80; PMID:1207728; http://dx.doi.org/10. 1038/258577a0.
2. Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. B lymphocyte proliferation is suppressed by the opi-oid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology 2011; 216:173-83; PMID:20598772; http://dx.doi.org/10.1016/j. imbio.2010.06.001.
3. Bodnar RJ. Endogenous opiates and behavior: 2008. Peptides 2009; 30:2432-79; PMID:19793543; http://dx.doi.org/10.1016/j.peptides.2009.09.027.
4. Bodnar RJ. Endogenous opiates and behavior: 2010. Peptides 2011; 32:2522-52; PMID:21983105; http://dx.doi.org/10.1016/j.peptides.2011.09.020.
5. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. Endogenous opioids: biology and function. Annu Rev Neurosci 1984; 7:223-55; PMID:6324644; http://dx.doi.org/10.1146/annurev.ne.07.030184.001255.
6. Sharma HS. Interaction between amino acid neurotransmitters and opioid receptors in hyperther-mia-induced brain pathology. Prog Brain Res 2007; 162:295-317; PMID:17645925; http://dx.doi.org/10.1016/S0079-6123(06)62015-3.
7. Deroee A F, Nezami BG, Mehr SE, Hosseini R, Salmasi AH, Talab SS, et al.; Armin FarajzadehDeroee. Cholestasis induced nephrotoxicity: the role of endogenous opioids. Life Sci 2010; 86:488-92; PMID:20153756; http://dx.doi.org/10.1016/j.lfs.2010.02.005.
8. Plow EB, Pascual-Leone A, Machado A. Brain stimulation in the treatment of chronic neuropathic and non-cancerous pain. J Pain 2012; 13:411-24; PMID:22484179; http://dx.doi.org/10.1016/j.jpain.2012.02.001.
9. Kishori B, Reddy PS. Role of methionine-enkephalin on the regulation of carbohydrate metabolism in the rice field crab Oziotelphusa senex senex. C R Biol 2005; 328:812-20; PMID:16168362; http://dx.doi.org/10.1016/j.crvi.2005.07. 001.
10. Pellizzari EH, Barontini M, Figuerola MdeL, Cigorraga SB, Levin G. Possible autocrine enkephalin regulation of catecholamine release in human pheochromocytoma cells. Life Sci 2008; 83:413-20; PMID:18706432; http://dx.doi.org/10.1016/j.lfs.2008.07.004.
11. McLaughlin PJ, Keiper CL, Verderame MF, Zagon IS. Targeted overexpression of OGFr in epithelium of transgenic mice suppresses cell proliferation and impairs full-thickness wound closure. Am J Physiol Regul Integr Comp Physiol 2012; 302:R1084-90; PMID:22338080; http://dx.doi.org/10.1152/ajp-regu.00670. 2011.
12. Donahue RN, McLaughlin PJ, Zagon IS. Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer. Exp Biol Med (Maywood) 2012; 237:167-77; PMID:22328595; http://dx.doi.org/10.1258/ebm. 2011.011321.
13. Fanning J, Hossler CA, Kesterson J P, Donahue RN, McLaughlin PJ, Zagon IS. Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer. Gynecol Oncol 2012; 124:319-24; PMID:22037317; http://dx.doi.org/10.1016/j.ygyno.2011.10.024.
14. Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood) 2011; 236:1036-50; PMID:21807817; http://dx.doi.org/10.1258/ebm.2011. 011121.
15. Lou HG, Ruan ZR, Jiang B. Quantitative determination of pidotimod in human plasma by liquid chromatography tandem mass spectrometry: application to a bioequivalence study. Arzneimittelforschung 2012; 62:99-104; PMID:22344555; http://dx.doi.org/10.1055/s-0031-1297983.
16. Riboldi P, Gerosa M, Meroni PL. Pidotimod: a reappraisal. Int J Immunopathol Pharmacol 2009; 22:255-62; PMID:19505378.
17. Masihi KN. Immunomodulatory agents for prophylaxis and therapy of infections. Int J Antimicrob Agents 2000; 14:181-91; PMID:10773486; http://dx.doi.org/10.1016/S0924-8579(99)00161-2.
18. La Mantia I, Grillo C, Mattina T, Zaccone P, Xiang M, Di Mauro M, et al. Prophylaxis with the novel immunomodulator pidotimod reduces the frequency and severity of upper respiratory tract infections in children with Down's syndrome. J Chemother 1999; 11:126-30; PMID:10326743.
19. Aivazis V, Hatzimichail A, Papachristou A, Valeri R, Iuga-Donca G. Clinical evaluation and changes of the respiratory epithelium function after administration of Pidotimod in Greek children with recurrent respiratory tract infections. Minerva Pediatr 2002; 54:315-9; PMID:12131867.
20. Van Nuffel AM, Tuyaerts S, Benteyn D, Wilgenhof S, Corthals J, Heirman C, et al. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. J Immunol Methods 2012; 377:23-36; PMID:22269772; http://dx.doi.org/10.1016/j.jim. 2011.12.010.
21. Crispin JC, Alcocer-Varela J. The role myeloid dendritic cells play in the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2007; 6:450-6; PMID:17643932; http://dx.doi.org/10.1016/j.aut-rev.2007.01.014.
22. Saha A, Chatterjee SK. Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice. Cell Immunol 2010; 263:9-21; PMID:20236626; http://dx.doi.org/10.1016/j.cel-limm.2010.02.010.
23. Moser JM, Sassano ER, Leistritz C, Eatrides JM, Phogat S, Koff W, et al. Optimization of a dendritic cell-based assay for the in vitro priming of naïve human CD4+ T cells. J Immunol Methods 2010; 353:8-19; PMID:19925804; http://dx.doi.org/10.1016/j.jim.2009.11.006.
24. Hargadon KM, Forrest OA, Reddy PR. Suppression of the maturation and activation of the dendritic cell line DC2.4 by melanoma-derived factors. Cell Immunol 2012; 272:275-82; PMID:22051048; http://dx.doi.org/10.1016/j.cellimm. 2011.10.003.
25. Trepiakas R, Pedersen AE, Met Ö, Svane IM. Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. Vaccine 2009; 27:2213-9; PMID:19428835; http://dx.doi.org/10.1016/j.vaccine.2009.02.015.
26. Giagulli C, Noerder M, Avolio M, Becker PD, Fiorentini S, Guzman CA, et al. Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal muco-sa level. Int Immunopharmacol 2009; 9:1366-73; PMID:19712757; http://dx.doi.org/10.1016/j.intimp.2009.08.010.
27. Shan F, Xia Y, Wang N, Meng J, Lu C, Meng Y, et al. Functional modulation of the pathway between dendritic cells (DCs) and CD4+T cells by the neuropeptide: methionine enkephalin (MENK). Peptides 2011; 32:929-37; PMID:21335041; http://dx.doi.org/10.1016/j.peptides.2011.01.033.
28. McLaughlin PJ, Sassani J W, Klocek MS, Zagon IS. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review. Brain Res Bull 2010; 81:236-47; PMID:19683562; http://dx.doi.org/10.1016/j.brainresbull.2009.08.008.
29. Hoyle CH. Evolution of neuronal signalling: transmitters and receptors. Auton Neurosci 2011; 165:28-53; PMID:20646967; http://dx.doi.org/10.1016/j.aut- neu.2010.05.007.
30. Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. T lymphocyte proliferation is suppressed by the opi-oid growth factor ([Met(5)]-enkephalin)- opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Immunobiology 2011; 216:579-90; PMID:20965606; http://dx.doi.org/10. 1016/j.imbio.2010.09.014.
31. Donahue RN, McLaughlin PJ, Zagon IS. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am J Physiol Regul Integr Comp Physiol 2009; 296:R1716-25; PMID:19297547; http://dx.doi.org/10.1152/ajpregu.00075.2009.
32. Cheng F, Zagon IS, Verderame MF, McLaughlin PJ. The OGF-OGFr axis utilizes the p16 pathway to inhibit progression of human squamous cell carcinoma of the head and neck. Cancer Res 2007; 67:10511-8; PMID:17974995; http://dx.doi.org/10.1158/0008-5472.CAN-07-1922.
33. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer 2008; 7:5-17; PMID:18190706; http://dx.doi.org/10.1186/1476-4598-7-5.
34. Cheng F, McLaughlin PJ, Verderame M F, Zagon IS. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell 2009; 20:319-27; PMID:18923142; http://dx.doi.org/10.1091/mbc.E08-07-0681.
35. Zagon IS, Gibo DM, McLaughlin PJ. Zeta (zeta), a growth-related opioid receptor in developing rat cerebellum: identification and characterization. Brain Res 1991; 551:28-35; PMID:1655161; http://dx.doi.org/10.1016/0006-8993(91) 90909-F.
36. Zagon IS, Verderame M F, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 2002; 38:351-76; PMID:11890982; http://dx.doi.org/10.1016/S0165-0173(01)00160-6.
37. Klocek MS, Sassani JW, Donahue RN, McLaughlin PJ, Zagon IS. Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis. Invest Ophthalmol Vis Sci 2010; 51:5054-61; PMID:20463323; http://dx.doi.org/10.1167/iovs.09-4949.
38. McLaughlin PJ, Zagon IS, Park SS, Conway A, Donahue RN, Goldenberg D. Growth inhibition of thyroid follicular cell-derived cancers by the opi-oid growth factor (OGF)-opioid growth factor receptor (OGFr) axis. BMC Cancer 2009; 9:369; PMID:19835629; http://dx.doi.org/10.1186/1471-2407-9-369.
39. Jaglowski JR, Zagon IS, Stack BC Jr., Verderame M F, Leure-duPree AE, Manning JD, et al. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2005; 56:97-104; PMID:15791460; http://dx.doi.org/10.1007/s00280-004-0929-4.
40. Hua H, Lu C, Li W, Meng J, Wang D, Plotnikoff N P, et al.; HuiHua. Comparison of stimulating effect on subpopulations of lymphocytes in human peripheral blood by methionine enkephalin with IL-2 and IFN-γ. Hum Vaccin Immunother 2012; 8:1082-9; PMID:22854663.
41. Liu J, Chen W, Meng J, Lu C, Wang E, Shan F. Differentiation and Modulation of bone marrow progenitor of dendritic cell induced by methionine encephalin (MENK). Cancer Immunol Immmunother 2012
42. Chen W. Modulation of macrophage polarization promoting tumoricidal responses by neuropeptide: methionine encephalin (MENK). Cancer Immunol Immmunother 2012; http://dx.doi.org/10.1007/s00262-012-1240-6
43. Ronald N. Literature-related discovery: Potential treatments and preventatives for SARS. Technol Forecast Soc Change 2011; 78:1164-73; http://dx.doi.org/10.1016/j.techfore.2011.03.022.
44. Jara-Pérez J V, Berber A. Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial. Clin Ther 2000; 22:748-59; PMID:10929921; http://dx.doi.org/10.1016/S0149-2918(00)90008-0.
45. Kammona O, Kiparissides C. Recent advances in nanocarrier-based mucosal delivery of biomolecules. J Control Release 2012; 161:781-94; PMID:22659331; http://dx.doi.org/10.1016/j.jconrel.2012.05.040.
46. Cherwonogrodzky J W. Research strategies for the treatment of biothreats. Curr Opin Pharmacol 2005; 5:465-72; PMID:16084772; http://dx.doi.org/10.1016/j. coph.2005.04.011.
47. Noh YW, Jang YS, Ahn KJ, Lim YT, Chung BH. Simultaneous in vivo tracking of dendritic cells and priming of an antigen-specific immune response. Biomaterials 2011; 32:6254-63; PMID:21620470.
48. Jeong YJ, Hong SW, Kim JH, Jin DH, Kang JS, Lee WJ, et al.; Young-JooJeong. Vitamin C-treated murine bone marrow-derived dendritic cells preferentially drive naïve T cells into Th1 cells by increased IL-12 secretions. Cell Immunol 2011; 266:192-9; PMID:21074755; http://dx.doi.org/10. 1016/j.cel-limm.2010.10.005.
49. Johansson C, Ingman M, Jo Wick M. Elevated neu-trophil, macrophage and dendritic cell numbers characterize immune cell populations in mice chronically infected with Salmonella. Microb Pathog 2006; 41:49-58; PMID:16782300; http://dx.doi.org/10.1016/j.micpath.2006.03.004.
50. Hadeiba H, Lahl K, Edalati A, Oderup C, Habtezion A, Pachynski R, et al.; HuseinHadeiba. Plasmacytoid dendritic cells transport peripheral antigens to the thymus to promote central tolerance. Immunity 2012; 36:438-50; PMID:22444632; http://dx.doi.org/10.1016/j.immuni.2012.01.017.
51. Jung NC, Kim HJ, Kang MS, Lee JH, Song JY, Seo HG, et al. Photodynamic therapy-mediated DC immunotherapy is highly effective for the inhibition of established solid tumors. Cancer Lett 2012; 324:58-65; PMID:22554711; http://dx.doi.org/10.1016/j.canlet.2012.04.024.
52. Wu G F, Shindler KS, Allenspach EJ, Stephen TL, Thomas HL, Mikesell RJ, et al. Limited sufficiency of antigen presentation by dendritic cells in models of central nervous system autoimmunity. J Autoimmun 2011; 36:56-64; PMID:21095100; http://dx.doi.org/10.1016/j.jaut.2010.10.006.
53. Gottenberg JE, Chiocchia G. Dendritic cells and interferon-mediated autoimmunity. Biochimie 2007; 89:856-71; PMID:17562353; http://dx.doi.org/10. 1016/j.biochi.2007.04.013.
54. Torres-Aguilar H, Blank M, Jara LJ, Shoenfeld Y. Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. Autoimmun Rev 2010; 10:8-17; PMID:20678591; http://dx.doi.org/10. 1016/j.aut-rev.2010.07.015.
55. Moyer JS, Maine G, Mulé JJ. Early vaccination with tumor-lysate-pulsed dendritic cells after allo-geneic bone marrow transplantation has antitumor effects. Biol Blood Marrow Transplant 2006; 12:1010-9; PMID:17084367; http://dx.doi.org/10.1016/j.bbmt.2006.06.009.
56. Hashimoto D, Merad M. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome. Semin Immunol 2011; 23:50-7; PMID:21316261; http://dx.doi.org/10.1016/j.smim.2011.01.005.
57. Young JW, Merad M, Hart DN. Dendritic cells in transplantation and immune-based therapies. Biol Blood Marrow Transplant 2007; 13(Suppl 1):23-32; PMID:17222766; http://dx.doi.org/10.1016/j.bbmt.2006.10.023.
58. Ian S, Zagon M F, Verderame SS, Allen PJ. Cloning, sequencing, chromosomal wcation, and function of a cDNA encoding the opioid growth factor receptor (OGFR) in humans and a modulator of ogf activity in the growth of pancreatic and colorectal cancer. Gastroenterology 2000; 118:417; http://dx.doi.org/10.1016/S0016-5085(00)83780-4.
59. Avella DM, Kimchi ET, Donahue RN, Tagaram HR, McLaughlin PJ, Zagon IS, et al. The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of humanhepatocellular cancer. Am J Physiol Regul Integr Comp Physiol 2010; 298:459-66; http://dx.doi.org/10.1152/ajpregu.00646.2009.
60. McLaughlin PJ, Zagon IS, Park SS, Conway A, Donahue RN, Goldenberg D. Growth inhibition of thyroid follicular cell-derived cancers by the opi-oid growth factor (OGF)-opioid growth factor receptor (OGFr) axis. BMC Cancer 2009; 9:369; PMID:19835629; http://dx.doi.org/10.1186/1471-2407-9-369.
61. McLaughlin PJ, Levin RJ, Zagon IS. Opioid growth factor (OGF) inhibits the progression of human squa-mous cell carcinoma of the head and neck transplanted into nude mice. Cancer Lett 2003; 199:209-17; PMID:12969794; http://dx.doi.org/10.1016/S0304-3835(03)00341-0.
62. Di Renzo M, Pasqui AL, Bruni F, Saletti M, Bova G, Chiarion C, et al. The in vitro effect of pidoti-mod on some immune function in cancer patients. Immunopharm Immunot 1997; 19:37-51; http://dx.doi.org/10.3109/08923979709038532.
63. Castillo EA, Dea-Ayuela MA, Bolás-Fernández F, Rangel M, González-Rosende ME. The kinetoplas-tid chemotherapy revisited: current drugs, recent advances and future perspectives. Curr Med Chem 2010; 17:4027-51; PMID:20939823; http://dx.doi.org/10.2174/092986710793205345.
64. Ito A, Fujioka M, Tanaka K, Kobayashi T, Honda H. Screening of cytokines to enhance vaccine effects of heat shock protein 70-rich tumor cell lysate. J Biosci Bioeng 2005; 100:36-42; PMID:16233848; http://dx.doi.org/10.1263/jbb.100. 36.
65. Kao JY, Zhang M, Chen CM, Pierzchala A, Chen JJ. Aberrant T helper cell response in tumor-bearing mice limits the efficacy of dendritic cell vaccine. Immunol Lett 2006; 105:16-25; PMID:16388858; http://dx.doi.org/10.1016/j.imlet. 2005.11.026.
66. Frankenberger B, Schendel DJ. Third generation dendritic cell vaccines for tumor immunotherapy. Eur J Cell Biol 2012; 91:53-8; PMID:21439674; http://dx.doi.org/10.1016/j.ejcb.2011.01.012.
67. Cho D-Y, Yang W-K, Lee H-C, Hsu D-M, Lin H-L, Lin S-Z, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg 2012; 77:736-44; PMID:22120301; http://dx.doi.org/10.1016/j.wneu.2011.08.020.
68. Hamdy S, Haddadi A, Hung RW, Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 2011; 63:943-55; PMID:21679733; http://dx.doi.org/10.1016/j.addr.2011.05.021.
69. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176:1693-702; PMID:1460426; http://dx.doi.org/10.1084/jem.176.6.1693.